Filgrastim (Neupogen, Nivestym, Zarxio, Releuko)_Non-oncology

Filgrastim (Neupogen, Nivestym, Zarxio, Releuko) is covered only for specified non‑oncology indications—severe chronic neutropenias (congenital, cyclic, idiopathic), HIV/AIDS‑associated neutropenia, and non‑chemotherapy drug‑induced agranulocytosis/neutropenia—and is not covered for uses outside those FDA‑approved or compendial indications. Approvals are time‑limited (6 months for severe chronic neutropenia, 4 months for HIV/AIDS, 1 month for drug‑induced), require documentation of the approved indication and prescribing/consultation by specified specialists (hematologist, infectious disease/HIV specialist as applicable), and dosing must be within limits (≤12 mcg/kg/day for severe chronic; ≤10 mcg/kg/day for HIV/AIDS or drug‑induced).

"When requesting filgrastim (Neupogen, Nivestym, Zarxio, Releuko) for non-oncology indications, the individual requiring treatment must be diagnosed with an FDA-approved indication or approved compe..."